Mutation processes in 293-based clones overexpressing the DNA cytosine deaminase APOBEC3B

PLoS ONE

Volumn 11, Issue 5, 2016, Pages

  Akre, Monica K ^a   Starrett, Gabriel J ^a   Quist, Jelmar S ^b   Temiz, Nuri A ^a   Carpenter, Michael A ^a   Tutt, Andrew N J ^b   Grigoriadis, Anita ^b   Harris, Reuben S ^a,c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b GUY S HOSPITAL   (United Kingdom)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSINE; CYTOSINE DEAMINASE; GENOMIC DNA; GREEN FLUORESCENT PROTEIN; MYC PROTEIN; PROTEIN APOBEC3B; PROTEIN P53; UNCLASSIFIED DRUG; APOBEC3B PROTEIN, HUMAN; CYTIDINE DEAMINASE; DOXYCYCLINE; ENHANCED GREEN FLUORESCENT PROTEIN; HYBRID PROTEIN; MINOR HISTOCOMPATIBILITY ANTIGEN; MYC PROTEIN, HUMAN; THYMINE; TP53 PROTEIN, HUMAN;

ARTICLE; CELL DEATH; CLONE; CONTROLLED STUDY; COPY NUMBER VARIATION; DEAMINATION; DNA SEQUENCE; ENZYME ACTIVITY; GENE SEQUENCE; GENOME; GENOME-WIDE ASSOCIATION STUDY; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; MISMATCH REPAIR; MUTAGENESIS; MUTATIONAL ANALYSIS; NEOPLASM; PHENOTYPE; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; CELL CLONE; CELL ENGINEERING; CELL LINE; CHEMISTRY; GENE EXPRESSION REGULATION; GENE VECTOR; GENETIC TRANSFECTION; GENETICS; HEK293 CELL LINE; METABOLISM; MUTATION; NUCLEOTIDE SEQUENCE; PROCEDURES; TISSUE MICROARRAY;

BASE SEQUENCE; CELL DEATH; CELL ENGINEERING; CELL LINE; CLONE CELLS; CYTIDINE DEAMINASE; CYTOSINE; DNA MISMATCH REPAIR; DOXYCYCLINE; GENE EXPRESSION REGULATION; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HEK293 CELLS; HUMANS; MINOR HISTOCOMPATIBILITY ANTIGENS; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS C-MYC; RECOMBINANT FUSION PROTEINS; THYMINE; TISSUE ARRAY ANALYSIS; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84969769378     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0155391     Document Type: Article

References (64)

1. Roberts SA, Gordenin DA. Hypermutation in human cancer genomes: footprints and mechanisms. Nature reviews. 2014; 14(12):786-800. doi: 10.1038/nrc3816 PMID: 25417590.
2. Swanton C, McGranahan N, Starrett GJ, Harris RS. APOBEC enzymes: mutagenic fuel for cancer evolution and heterogeneity. Cancer Discov. 2015; 5(7):704-12. doi: 10.1158/2159-8290.CD-15-0344 PMID: 26091828; PubMed Central PMCID: PMC4497973.
3. Henderson S, Fenton T. APOBEC3 genes: retroviral restriction factors to cancer drivers. Trends Mol Med. 2015; 21(5):274-84. doi: 10.1016/j.molmed.2015.02.007 PMID: 25820175.
4. Helleday T, Eshtad S, Nik-Zainal S. Mechanisms underlying mutational signatures in human cancers. Nat Rev Genet. 2014; 15(9):585-98. doi: 10.1038/nrg3729 PMID: 24981601.
5. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature. 2013; 500(7463):415-21. Epub 2013/08/16. doi: 10.1038/nature12477 nature12477 [pii]. PMID: 23945592.
6. Cleaver JE, Crowley E. UV damage, DNA repair and skin carcinogenesis. Front Biosci. 2002; 7:d1024-43. Epub 2002/03/19. PMID: 11897551.
7. Hecht SS. Lung carcinogenesis by tobacco smoke. Int J Cancer. 2012; 131(12):2724-32. Epub 2012/09/05. doi: 10.1002/ijc.27816 PMID: 22945513; PubMed Central PMCID: PMC3479369.
8. Poon SL, Pang ST, McPherson JR, Yu W, Huang KK, Guan P, et al. Genome-wide mutational signatures of aristolochic acid and its application as a screening tool. Sci Transl Med. 2013; 5(197):197ra01. doi: 10.1126/scitranslmed.3006086 PMID: 23926199.
9. Poon SL, Huang MN, Choo Y, McPherson JR, Yu W, Heng HL, et al. Mutation signatures implicate aristolochic acid in bladder cancer development. Genome medicine. 2015; 7(1):38. doi: 10.1186/s13073-015-0161-3 PMID: 26015808; PubMed Central PMCID: PMC4443665.
10. Lord CJ, Tutt AN, Ashworth A. Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors. Annu Rev Med. 2015; 66:455-70. doi: 10.1146/annurev-med-050913-022545 PMID: 25341009.
11. Nik-Zainal S, Alexandrov LB, Wedge DC, Van Loo P, Greenman CD, Raine K, et al. Mutational processes molding the genomes of 21 breast cancers. Cell. 2012; 149(5):979-93. Epub 2012/05/23. S0092-8674(12)00528-4 [pii] doi: 10.1016/j.cell.2012.04.024 PMID: 22608084.
12. Roberts SA, Sterling J, Thompson C, Harris S, Mav D, Shah R, et al. Clustered mutations in yeast and in human cancers can arise from damaged long single-strand DNA regions. Mol Cell. 2012; 46(4):424-35. doi: 10.1016/j.molcel.2012.03.030 PMID: 22607975; PubMed Central PMCID: PMC3361558.
13. Burns MB, Lackey L, Carpenter MA, Rathore A, Land AM, Leonard B, et al. APOBEC3B is an enzymatic source of mutation in breast cancer. Nature. 2013; 494(7437):366-70. Epub 2013/02/08. doi: 10.1038/nature11881 nature11881 [pii]. PMID: 23389445.
14. Burns MB, Temiz NA, Harris RS. Evidence for APOBEC3B mutagenesis in multiple human cancers. Nat Genet. 2013; 45(9):977-83. Epub 2013/07/16. doi: 10.1038/ng.2701 ng.2701 [pii]. PMID: 23852168.
15. Roberts SA, Lawrence MS, Klimczak LJ, Grimm SA, Fargo D, Stojanov P, et al. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat Genet. 2013; 45(9):970-6. doi: 10.1038/ng.2702 PMID: 23852170; PubMed Central PMCID: PMC3789062.
16. Albin JS, Harris RS. Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics. Expert Rev Mol Med. 2010; 12:e4. Epub 2010/01/26. S1462399409001343 [pii] doi: 10.1017/S1462399409001343 PMID: 20096141; PubMed Central PMCID: PMC2860793.
17. Harris RS, Dudley JP. APOBECs and virus restriction. Virology. 2015;479-480C:131-45. doi: 10.1016/j.virol.2015.03.012 PMID: 25818029; PubMed Central PMCID: PMC4424171.
18. Bacolla A, Cooper DN, Vasquez KM. Mechanisms of base substitution mutagenesis in cancer genomes. Genes. 2014; 5(1):108-46. doi: 10.3390/genes5010108 PMID: 24705290; PubMed Central PMCID: PMC3978516.
19. Lackey L, Law EK, Brown WL, Harris RS. Subcellular localization of the APOBEC3 proteins during mitosis and implications for genomic DNA deamination. Cell Cycle. 2013; 12(5):762-72. Epub 2013/02/08. doi: 10.4161/cc.23713 23713 [pii]. PMID: 23388464; PubMed Central PMCID: PMC3610724.
20. Leonard B, Hart SN, Burns MB, Carpenter MA, Temiz NA, Rathore A, et al. APOBEC3B upregulation and genomic mutation patterns in serous ovarian carcinoma. Cancer Res. 2013; 73(24):7222-31. Epub 2013/10/25. doi: 10.1158/0008-5472.CAN-13-1753 PMID: 24154874; PubMed Central PMCID: PMC3867573.
21. Taylor BJ, Nik-Zainal S, Wu YL, Stebbings LA, Raine K, Campbell PJ, et al. DNA deaminases induce break-associated mutation showers with implication of APOBEC3B and 3A in breast cancer kataegis. Elife. 2013; 2:e00534. Epub 2013/04/20. doi: 10.7554/eLife.00534 00534 [pii]. PMID: 23599896; PubMed Central PMCID: PMC3628087.
22. Shinohara M, Io K, Shindo K, Matsui M, Sakamoto T, Tada K, et al. APOBEC3B can impair genomic stability by inducing base substitutions in genomic DNA in human cells. Sci Rep. 2012; 2:806. Epub 2012/11/15. doi: 10.1038/srep00806 PMID: 23150777; PubMed Central PMCID: PMC3496164.
23. Henderson S, Chakravarthy A, Su X, Boshoff C, Fenton TR. APOBEC-mediated cytosine deamination links PIK3CA helical domain mutations to human papillomavirus-driven tumor development. Cell Rep. 2014; 7(6):1833-41. doi: 10.1016/j.celrep.2014.05.012 PMID: 24910434.
24. de Bruin EC, McGranahan N, Mitter R, Salm M, Wedge DC, Yates L, et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science. 2014; 346(6206):251-6. doi: 10.1126/science.1253462 PMID: 25301630.
25. Sieuwerts AM, Willis S, Burns MB, Look MP, Meijer-Van Gelder ME, Schlicker A, et al. Elevated APOBEC3B correlates with poor outcomes for estrogen-receptor-positive breast cancers. Hormones & cancer. 2014; 5(6):405-13. doi: 10.1007/s12672-014-0196-8 PMID: 25123150; PubMed Central PMCID: PMC4228172.
26. Cescon DW, Haibe-Kains B, Mak TW. APOBEC3B expression in breast cancer reflects cellular proliferation, while a deletion polymorphism is associated with immune activation. Proc Natl Acad Sci U S A. 2015; 112(9):2841-6. doi: 10.1073/pnas.1424869112 PMID: 25730878.
27. Leonard B, McCann JL, Starrett GJ, Kosyakovsky L, Luengas EM, Molan AM, et al. The PKC/NF-kappaB signaling pathway induces APOBEC3B expression in multiple human cancers. Cancer Res. 2015; 75(21):4538-47. doi: 10.1158/0008-5472.CAN-15-2171-T PMID: 26420215; PubMed Central PMCID: PMC4631676.
28. Vieira VC, Leonard B, White EA, Starrett GJ, Temiz NA, Lorenz LD, et al. Human papillomavirus E6 triggers upregulation of the antiviral and cancer genomic DNA deaminase APOBEC3B. MBio. 2014; 5(6). doi: 10.1128/mBio.02234-14 PMID: 25538195; PubMed Central PMCID: PMC4278539.
29. Warren CJ, Xu T, Guo K, Griffin LM, Westrich JA, Lee D, et al. APOBEC3A functions as a restriction factor of human papillomavirus. J Virol. 2015; 89(1):688-702. doi: 10.1128/JVI.02383-14 PMID: 25355878; PubMed Central PMCID: PMC4301161.
30. Mori S, Takeuchi T, Ishii Y, Kukimoto I. Identification of APOBEC3B promoter elements responsible for activation by human papillomavirus type 16 E6. Biochem Biophys Res Commun. 2015; 460(3):555-60. doi: 10.1016/j.bbrc.2015.03.068 PMID: 25800874.
31. Periyasamy M, Patel H, Lai CF, Nguyen VT, Nevedomskaya E, Harrod A, et al. APOBEC3B-mediated cytidine deamination is required for estrogen receptor action in breast cancer. Cell Rep. 2015; 13 (1):108-21. doi: 10.1016/j.celrep.2015.08.066 PMID: 26411678; PubMed Central PMCID: PMC4597099.
32. Land AM, Wang J, Law EK, Aberle R, Kirmaier A, Krupp A, et al. Degradation of the cancer genomic DNA deaminase APOBEC3B by SIV Vif. Oncotarget. 2015; 6(37):39969-79. doi: 10.18632/oncotarget.5483 PMID: 26544511.
33. Carpenter MA, Li M, Rathore A, Lackey L, Law EK, Land AM, et al. Methylcytosine and normal cytosine deamination by the foreign DNA restriction enzyme APOBEC3A. J Biol Chem. 2012; 287(41):34801-8. Epub 2012/08/17. doi: 10.1074/jbc.M112.385161 M112.385161 [pii]. PMID: 22896697; PubMed Central PMCID: PMC3464582.
34. Suspène R, Aynaud MM, Guetard D, Henry M, Eckhoff G, Marchio A, et al. Somatic hypermutation of human mitochondrial and nuclear DNA by APOBEC3 cytidine deaminases, a pathway for DNA catabolism. Proc Natl Acad Sci U S A. 2011; 108(12):4858-63. Epub 2011/03/04. 1009687108 [pii] doi: 10.1073/pnas.1009687108 PMID: 21368204; PubMed Central PMCID: PMC3064337.
35. Rasmussen M, Sundstrom M, Goransson Kultima H, Botling J, Micke P, Birgisson H, et al. Allele-specific copy number analysis of tumor samples with aneuploidy and tumor heterogeneity. Genome Biol. 2011; 12(10):R108. doi: 10.1186/gb-2011-12-10-r108 PMID: 22023820; PubMed Central PMCID: PMC3333778.
36. Gehring JS, Fischer B, Lawrence M, Huber W. SomaticSignatures: inferring mutational signatures from single-nucleotide variants. Bioinformatics. 2015; 31(22):3673-5. doi: 10.1093/bioinformatics/btv408 PMID: 26163694.
37. Haradhvala NJ, Polak P, Stojanov P, Covington KR, Shinbrot E, Hess JM, et al. Mutational strand asymmetries in cancer genomes reveal mechanisms of DNA damage and repair. Cell. 2016; 164 (3):538-49. doi: 10.1016/j.cell.2015.12.050 PMID: 26806129; PubMed Central PMCID: PMC4753048.
38. Suspène R, Henry M, Guillot S, Wain-Hobson S, Vartanian JP. Recovery of APOBEC3-edited human immunodeficiency virus G->A hypermutants by differential DNA denaturation PCR. J Gen Virol. 2005; 86(Pt 1):125-9. PMID: 15604439.
39. Stenglein MD, Burns MB, Li M, Lengyel J, Harris RS. APOBEC3 proteins mediate the clearance of foreign DNA from human cells. Nat Struct Mol Biol. 2010; 17(2):222-9. PMID: 20062055. doi: 10.1038/nsmb.1744
40. Liu M, Duke JL, Richter DJ, Vinuesa CG, Goodnow CC, Kleinstein SH, et al. Two levels of protection for the B cell genome during somatic hypermutation. Nature. 2008; 451(7180):841-5. PMID: 18273020. doi: 10.1038/nature06547
41. Nilsen H, An Q, Lindahl T. Mutation frequencies and AID activation state in B-cell lymphomas from Ung-deficient mice. Oncogene. 2005; 24(18):3063-6. doi: 10.1038/sj.onc.1208480 PMID: 15735713.
42. Mussil B, Suspene R, Aynaud MM, Gauvrit A, Vartanian JP, Wain-Hobson S. Human APOBEC3A isoforms translocate to the nucleus and induce DNA double strand breaks leading to cell stress and death. PloS one. 2013; 8(8):e73641. doi: 10.1371/journal.pone.0073641 PMID: 23977391; PubMed Central PMCID: PMC3748023.
43. Ramiro AR, Jankovic M, Eisenreich T, Difilippantonio S, Chen-Kiang S, Muramatsu M, et al. AID is required for c-myc/IgH chromosome translocations in vivo. Cell. 2004; 118(4):431-8. PMID: 15315756.
44. Rucci F, Cattaneo L, Marrella V, Sacco MG, Sobacchi C, Lucchini F, et al. Tissue-specific sensitivity to AID expression in transgenic mouse models. Gene. 2006; 377:150-8. doi: 10.1016/j.gene.2006.03.024 PMID: 16787714.
45. Komori J, Marusawa H, Machimoto T, Endo Y, Kinoshita K, Kou T, et al. Activation-induced cytidine deaminase links bile duct inflammation to human cholangiocarcinoma. Hepatology. 2008; 47(3):888-96. doi: 10.1002/hep.22125 PMID: 18306229.
46. Matsumoto Y, Marusawa H, Kinoshita K, Endo Y, Kou T, Morisawa T, et al. Helicobacter pylori infection triggers aberrant expression of activation-induced cytidine deaminase in gastric epithelium. Nat Med. 2007; 13(4):470-6. doi: 10.1038/nm1566 PMID: 17401375.
47. Koboldt DC, Zhang Q, Larson DE, Shen D, McLellan MD, Lin L, et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 2012; 22(3):568-76. doi: 10.1101/gr.129684.111 PMID: 22300766; PubMed Central PMCID: PMC3290792.
48. Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013; 31 (3):213-9. doi: 10.1038/nbt.2514 PMID: 23396013; PubMed Central PMCID: PMC3833702.
49. Di Noia JM, Neuberger MS. Molecular mechanisms of antibody somatic hypermutation. Annu Rev Biochem. 2007; 76:1-22. PMID: 17328676.
50. Rayner E, van Gool IC, Palles C, Kearsey SE, Bosse T, Tomlinson I, et al. A panoply of errors: polymerase proofreading domain mutations in cancer. Nature reviews. 2016; 16(2):71-81. doi: 10.1038/nrc.2015.12 PMID: 26822575.
51. Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology. 2010; 138 (6):2073-87 e3. doi: 10.1053/j.gastro.2009.12.064 PMID: 20420947; PubMed Central PMCID: PMC3037515.
52. Harris RS. Molecular mechanism and clinical impact of APOBEC3B-catalyzed mutagenesis in breast cancer. Breast Cancer Res. 2015; 17:8. doi: 10.1186/s13058-014-0498-3 PMID: 25848704; PubMed Central PMCID: PMC4303225.
53. Lin YC, Boone M, Meuris L, Lemmens I, Van Roy N, Soete A, et al. Genome dynamics of the human embryonic kidney 293 lineage in response to cell biology manipulations. Nat Commun. 2014; 5:4767. doi: 10.1038/ncomms5767 PMID: 25182477; PubMed Central PMCID: PMC4166678.
54. Roesner LM, Mielke C, Fahnrich S, Merkhoffer Y, Dittmar KE, Drexler HG, et al. Stable expression of MutLgamma in human cells reveals no specific response to mismatched DNA, but distinct recruitment to damage sites. J Cell Biochem. 2013; 114(10):2405-14. doi: 10.1002/jcb.24591 PMID: 23696135.
55. Trojan J, Zeuzem S, Randolph A, Hemmerle C, Brieger A, Raedle J, et al. Functional analysis of hMLH1 variants and HNPCC-related mutations using a human expression system. Gastroenterology. 2002; 122(1):211-9. PMID: 11781295.
56. Nik-Zainal S, Wedge DC, Alexandrov LB, Petljak M, Butler AP, Bolli N, et al. Association of a germline copy number polymorphism of APOBEC3A and APOBEC3B with burden of putative APOBEC-dependent mutations in breast cancer. Nat Genet. 2014; 46(5):487-91. doi: 10.1038/ng.2955 PMID: 24728294; PubMed Central PMCID: PMC4137149.
57. Chen H, Lilley CE, Yu Q, Lee DV, Chou J, Narvaiza I, et al. APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons. Curr Biol. 2006; 16(5):480-5. PMID: 16527742.
58. Thielen BK, McNevin JP, McElrath MJ, Hunt BV, Klein KC, Lingappa JR. Innate immune signaling induces high levels of TC-specific deaminase activity in primary monocyte-derived cells through expression of APOBEC3A isoforms. J Biol Chem. 2010; 285(36):27753-66. Epub 2010/07/10. M110.102822 [pii] doi: 10.1074/jbc.M110.102822 PMID: 20615867; PubMed Central PMCID: PMC2934643.
59. Hultquist JF, Lengyel JA, Refsland EW, LaRue RS, Lackey L, Brown WL, et al. Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1. J Virol. 2011; 85(21):11220-34. Epub 2011/08/13. JVI.05238-11 [pii] doi: 10.1128/JVI.05238-11 PMID: 21835787; PubMed Central PMCID: PMC3194973.
60. Aynaud MM, Suspene R, Vidalain PO, Mussil B, Guetard D, Tangy F, et al. Human Tribbles 3 protects nuclear DNA from cytidine deamination by APOBEC3A. J Biol Chem. 2012; 287(46):39182-92. Epub 2012/09/15. doi: 10.1074/jbc.M112.372722 M112.372722 [pii]. PMID: 22977230; PubMed Central PMCID: PMC3493958.
61. Land AM, Law EK, Carpenter MA, Lackey L, Brown WL, Harris RS. Endogenous APOBEC3A DNA cytosine deaminase is cytoplasmic and nongenotoxic. J Biol Chem. 2013; 288(24):17253-60. Epub 2013/05/04. doi: 10.1074/jbc.M113.458661 M113.458661 [pii]. PMID: 23640892; PubMed Central PMCID: PMC3682529.
62. Shee C, Cox BD, Gu F, Luengas EM, Joshi MC, Chiu LY, et al. Engineered proteins detect spontaneous DNA breakage in human and bacterial cells. Elife. 2013; 2:e01222. doi: 10.7554/eLife.01222 PMID: 24171103; PubMed Central PMCID: PMC3809393.
63. Chan K, Roberts SA, Klimczak LJ, Sterling JF, Saini N, Malc EP, et al. An APOBEC3A hypermutation signature is distinguishable from the signature of background mutagenesis by APOBEC3B in human cancers. Nat Genet. 2015; 47(9):1067-72. doi: 10.1038/ng.3378 PMID: 26258849.
64. Caval V, Suspene R, Shapira M, Vartanian JP, Wain-Hobson S. A prevalent cancer susceptibility APOBEC3A hybrid allele bearing APOBEC3B 3′UTR enhances chromosomal DNA damage. Nat Commun. 2014; 5:5129. doi: 10.1038/ncomms6129 PMID: 25298230.